Viscart 48 mg (2%) 2,4 ml –Intra-Articular Injection
Warning: The content of this page is prepared only for healthcare professionals. If you are not a healthcare professional, consult a physician and/or pharmacist for more information.
Viscart 2% viscoelastic sodium hyaluronate solution for intraarticular injection
The package contains 2.4ml of viscoelastic solution in a disposable glass syringe suitable for intraarticular use.
Description:
Viscart 2% is a highly purified, high molecular weight sodium hyaluronate solution in a sterile, apirogenous, clear, non-inflammatory, physiological saline solution.
High purity sodium hyaluronate is obtained from bacteria by fermentation.
Viscart 2% is a product used to relieve stiffness and pain in patients' knees and other synovial joints with degenerative and traumatic changes. Viscart 2% contains 20 mg sodium hyaluronate, sodium chloride, disodium hydrogen phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate and water for injection.
Viscart 2% has a PH value of 6.8-7.6 and an omission of 300-350 mOsm/kg, similar to synovial fluid.
Features and Effectiveness
All synovial joints, especially weight-bearing joints, contain viscoelastic sodium hyaluronate. This substance has lubricating and shock-absorbing properties that allow normal and painless joint movement. In degenerative joint diseases (osteoarthritis), the viscoelasticity of synovial fluid is significantly impaired, leading to increased joint pressure and deterioration of articular cartilage, limiting joint movement and causing pain. Intra-articular application of high-purity sodium hyaluronate, which has excellent viscoelastic properties, can improve joint lubrication. The product's lubricating and shock-absorbing properties reduce pain and improve joint mobility. This effect can persist for several months following the recommended treatment cycle.
Indications
Viscart 2% is a non-pharmacological treatment and is resistant to simple analgesics (eg. Acetaminophen (paracetamol)) is indicated in knee pain in patients with osteoarthritis (OA) who are unable to respond adequately.